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18f-labelled triazolyl-linked 
argininamides targeting the 
neuropeptide Y Y1R for pet imaging 
of mammary carcinoma
Simone Maschauer1, Julian J. ott  1, Günther Bernhardt2, torsten Kuwert1, Max Keller2 & 
olaf prante  1
neuropeptide Y Y1 receptors (Y1R) have been found to be overexpressed in a number of different 
tumours, such as breast, ovarian or renal cell cancer. in mammary carcinoma the high Y1R density 
together with its high incidence of 85% in primary human breast cancers and 100% in breast cancer 
derived lymph node metastases attracted special attention. therefore, the aim of this study was 
the development of radioligands for Y1R imaging by positron emission tomography (pet) with a 
special emphasis on imaging agents with reduced lipophilicity to provide a pet ligand with improved 
biodistribution in comparison with previously published tracers targeting the Y1R. three new 
radioligands based on BIBP3226, bearing an 18F-fluoroethoxy linker (12), an 18F-PEG-linker (13) or an 
18F-fluoroglycosyl moiety (11) were radiosynthesised in high radioactivity yields. The new radioligands 
displayed Y1R affinities of 2.8 nM (12), 29 nM (13) and 208 nM (11) and were characterised in vitro 
regarding binding to human breast cancer MCF-7-Y1 cells and slices of tumour xenografts. In vivo, small 
animal PET studies were conducted in nude mice bearing MCF-7-Y1 tumours. The binding to tumours, 
solid tumour slices and tumour cells correlated well with the Y1R affinities. Although 12 and 13 showed 
displaceable and specific binding to Y1R in vitro and in vivo, the radioligands still need to be optimised 
to achieve higher tumour-to-background ratios for Y1R imaging by pet. Yet the present study is another 
step towards an optimized pet radioligand for imaging of Y1R in vivo.
Neuropeptide Y (NPY), peptide YY (PYY) and pancreatic polypeptide (PP) are 36 amino acid peptides forming 
a family of biologically active peptides, the so-called neuropeptide Y or pancreatic polypeptide family1. Today, 
five mammalian NPY receptors (YRs) are known from molecular cloning, the Y1R, Y2R, Y4R, Y5R and y6 recep-
tor2–4. The y6 receptor gene encodes a functionally active protein in mice, but is a pseudogene in humans and not 
present in the rat genome at all3. All five subtypes belong to the large superfamily of G-Protein Coupled Receptors 
(GPCRs) which are characterised as proteins located in the cell membrane consisting of seven transmembrane 
helices. The binding affinity of endogenous ligands is quite inhomogeneous: while NPY strongly binds to Y1R, 
Y2R and Y5R (EC50 values in the single-digit nanomolar range) its affinity to the Y4R subtype is lower by at least 
two orders of magnitude. In contrast, PP is the only endogenous ligand binding to Y4R at low nanomolar con-
centrations5. NPY is one of the most abundant neuropeptides in the central and peripheral nervous system. It is 
involved in the regulation of numerous physiological and pathophysiological processes, such as gastro-intestinal 
regulation, food intake and blood pressure.
Recently, Y1R and Y2R have been found to be overexpressed in a number of different tumours, such as ovarian 
cancer (Y1R and Y2R)6, neuroblastoma (Y2R only)7 or renal cell carcinomas (Y1R only)8. In mammary carcinoma, 
not only the high incidence of Y1Rs of 85% in malignant primary human breast tumours and 100% in breast 
cancer derived lymph node metastases attracted special attention, but also the high receptor density. In-vitro 
autoradiography studies on tumour slices with [125I]hPYY and non-radioactive, subtype-selective ligands for Y1R 
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and Y2R revealed high specific binding (up to >12000 dpm/mg) due to extremely high density of the receptors in 
breast cancer9. Interestingly, the neoplastic transformation comes along with a switch in YR subtype expression: 
while healthy breast tissue only expresses the subtype Y2R, the Y1R subtype was found in tumour tissue only or at 
least predominantly9. Therefore, the Y1R is a promising target for tumour diagnosis and targeted tumour therapy, 
due to the high receptor expression and the predominance of the Y1R subtype in breast cancer tissue.
As subtype selective ligands are highly attractive for specific targeting of Y1R-positive tumours, many 
efforts have been made to design such subtype selective ligands. In 2001, the Beck-Sickinger group reported 
the first Y1R-preferring NPY analogues. [Phe7,Pro34]pNPY showed the highest selectivity for Y1R over Y2R 
and Y5R (>1:3000-fold)10. This compound was further developed towards a 99mTc-labelled radioligand, 
[99mTc]Tc(CO)3-NαHis-Ac-[Phe7,Pro34]-NPY, which was also used in first human imaging studies11. Based on 
this work, we have reported the first 18F-labelled analogue of NPY, [Pra4([18F]FGlc),Phe7,Pro34]NPY, which was 
synthesised by 18F-fluoroglycosylation using the corresponding alkyne-functionalised peptide12.
Besides the peptidic NPY analogues, a number of non-peptide Y1R ligands have been reported, such as 
BIBP322613, BIBO330414, LY35789715 and Y1-97316. The latter was radiolabelled with fluorine-18, a positron 
emitting radionuclide with beneficial decay characteristics, i.e. a half-life of 110 min, a clean decay profile (97% 
positron emission, 3% electron capture) and a low positron energy (max. 0.635 MeV), resulting a low maximum 
positron range of 2.4 mm in water and therefore leading to high-resolution positron emission tomography (PET) 
images17. [18F]Y1-973 was studied as the first non-peptide Y1R antagonist to be successfully applied for in vivo 
imaging of Y1R in the central nervous system (CNS) of monkeys16. However, this compound is most likely not 
suitable for peripheral imaging of breast cancer due to its high lipophilicity. The (R)-argininamide BIBP3226 
was described as the first highly potent and selective Y1R antagonist in 199413. Recently, we reported proto-
typic 18F-labelled argininamide-type Y1R antagonists derived from BIBP3226 as candidate radioligands for PET 
(1–4, Table 1)18. The most favorable compound (118, Table 1) was an amine-functionalised carbamoyl-derivative 
of BIBP3226 which was synthesised by 18F-fluoroacylation using 4-nitrophenyl-2-[18F]fluoropropionate ([18F]
NPFP). This ligand is highly potent (Ki (Y1R) = 1.3 nM) and subtype selective (>1:3000 over Y2R and >1:10000 
over Y4R and Y5R) and showed excellent in vivo-stability in mice. In nude mice bearing Y1R-positive MCF-7 
tumour xenografts, the compound showed a rapid blood clearance, but extraordinarily high accumulation in 
the gall bladder (>200%ID/g at 30 min p.i.). With only 0.51%ID/g at 30 min p.i., the tumour uptake was low, but 
compound structure Ki [nM] ±SEM n
BIBP322613 R1 1.3 ±0.2a 2
1 (equals number 23 in ref.18) R1 1.3 ±0.4a 2
2 (equals number 39 in ref.18) R1 1.3 ±0.6a 2
3 (equals number 41 in ref.18) R1 2000 ±180a 2
7 R1 0.94 ±0.11b 3
11 R2 208 ±24b 3
12 R2 2.8 ±0.7b 5
13 R2 29.0 ±3.6b 3
Table 1. Structures and Y1R binding affinities of BIBP3226, alkyne precursors 218 and 7, and the potential Y1R 
selective PET ligands 1, 318 and 11–13. Dissociation constants (Ki) were determined by displacement of a[3H]
UR-MK11419 or b[3H]UR-MK29922 at Y1R-expressing SK-N-MC neuroblastoma cells. Mean values ± SEM are 
given from n independent experiments performed in duplicate or triplicate.
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Figure 1. Synthesis of the alkyne-functionalised argininamide 7, serving as a precursor for click chemistry-
based 18F-labelling (see Fig. 2), and preparation of the potential Y1R ligands 11–13. Reagents and chemical 
yields: (a) HgCl2, DMF, DIPEA, 26%; (b) TFA, CH2Cl2, quantitative; (c) copper(II) acetate, sodium ascorbate, 
solvent: tert-butanol/water (11) or tert-butanol/water/acetonitrile (12, 13), 53% (11), 45% (12), 26% (13).
Figure 2. Radiosynthesis of [18F]11, [18F]12 and [18F]13. Reagents and conditions: (a) [18F]8, [18F]9 or [18F]10, 
Cu(OAc)2, sodium ascorbate, THPTA, pH 8, 60 °C, 15 min.
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the radioligand showed good retention in the tumour (0.43%ID/g at 90 min p.i.). In comparison to the hydro-
philic peptide radioligand agonist [Pra4([18F]FGlc),Phe7,Pro34]NPY12, the uptake of the compound in the kidneys 
was reduced by a factor of 10, being the major advantage of the hydrophobic small molecule antagonist PET 
radioligand.
Based on these findings, the aim of this study was to reduce the lipophilicity of a candidate ligand in order to 
achieve a more suitable biodistribution with reduced biliary excretion and thus a better visibility of the tumour in 
PET imaging studies. Therefore, we synthesised three BIBP3226-derivatives, two with 18F-fluoroethoxy-linkers 
and one with an 18F-fluoroglucosyl moiety, and compared their properties in vitro on MCF-7-Y1 cells and in vivo 
using a nude mouse tumour xenograft model.
Results and Discussion
chemistry and radiochemistry. The alkynylated labelling precursor 7 was prepared from amine 419 by 
guanidinylation of 4 with the isothiourea derivative 5 in the presence of mercury(II) chloride yielding interme-
diate 6, which was treated with trifluoroacetic acid (TFA) to obtain alkyne 7 (Fig. 1). The latter was subjected to 
copper(I)-catalysed cycloadditions with azides 820, 9 and 10 yielding the potential Y1R ligands 11–13 in a purity 
of >95% (Fig. 1).
The radiosynthesis of [18F]11 was performed according to a copper-catalysed azide-alkyne cycloaddition 
(CuAAC)-based 18F-fluoroglycosylation method (Fig. 2)21. The BIBP3226-derived alkyne 7 was treated with 
6-deoxy-6-[18F]fluoroglucosyl azide [18F]8 in an aqueous solution at 60 °C for 15 min providing [18F]11 in a high 
radiochemical yield (RCY) of >80%. The product was isolated by semi-preparative radio-HPLC in a radioactivity 
yield (RAY) of about 20% (referred to [18F]fluoride) with a molar activity of 9 GBq/µmol at the end of synthesis 
(EOS). The radiochemical purity was analysed by radio-HPLC and was >99%.
The radiosyntheses of [18F]12 and [18F]13 followed the same protocol as for [18F]11, except that the depro-
tection step was omitted. Labelling of the tosylate-bearing precursors 20 or 21, provided [18F]9 and [18F]10, 
respectively, with excellent radiochemical yields in the range of 90% within 5 min. Radio-HPLC separation of 
the 18F-labelled fluoroethoxy azides [18F]9 and [18F]10 was achieved by radio-HPLC without any UV-peaks 
interfering with the radioactive product peak (see Supplementary Figs S1 and S2). The click chemistry reaction 
with BIBP3226-derived alkyne 7 was performed under similar reaction conditions as for the glucosyl derivative 
[18F]11 leading to high RCY of >70%. After HPLC-isolation a RAY of about 5% for [18F]12 and 10% for [18F]13 
(referred to [18F]fluoride) after 90 min, a molar activity of 5–6 GBq/µmol at EOS, and a radiochemical purity of 
>99% were achieved.
In-vitro characterisation. For the determination of the Y1R affinities of 11, 12 and 13 (synthesis see Fig. 1), 
competition binding assays were carried out using the radioligand [3H]UR-MK299 (Kd = 44 pM) on SK-N-MC 
neuroblastoma cells as described previously22. Ki values of 11–13 are provided in Table 1 together with refer-
ence values from literature for the previously published compounds 1–3 for comparison. The precursor alkyne 
7 was found to bind to the Y1R with an affinity of 0.94 nM and thus exhibiting a similar receptor affinity as 
BIBP3226 and the fluoroacylated compound 1 previously published by Keller et al. (both Ki = 1.3 nM)18. The 
6-deoxy-6-fluoroglycosyl derivative 11 bound with an affinity of 208 nM to the Y1 receptor, which is a 10-fold 
higher Y1R affinity compared to the 2-deoxy-2-fluoroglycosyl derivative 3 (Ki = 2000 nM, Table 1) which had 
a longer spacer moiety between the fluoroglycosyl moiety and the binding motif18. Although exhibiting a lower 
affinity to the Y1R by a factor of about 200 compared to the lead compound BIBP3226, this finding supported 
our hypothesis, that shortening the linker from ten to only three atoms (3 vs. 11, Table 1) would result in a less 
pronounced decrease in Y1R affinity. Compared to the glycosyl derivatives, the compounds bearing the less polar 
fluoroethoxy groups revealed higher Y1R affinities: The Ki value of 13 was determined to be 29 nM, which means 
that it has a sevenfold higher affinity than the fluoroglycosylated compound 11, and the affinity of ligand 12 com-
prising the short fluoroethoxy chain increased even more by one order of magnitude (Ki = 2.8 nM).
To assess the YR subtype selectivity profiles of the three potential Y1R ligands 11, 12 and 13, the affinities to 
the other subtypes of the neuropeptide Y receptor, Y2R, Y4R and Y5R, were determined (Table S1, Supplementary 
Information). None of the three compounds showed considerable binding to one of the other subtypes within the 
experimental range of concentrations (maximum concentration of 10 µM), confirming the subtype selectivity for 
Y1R of the ligands under study (11–13).
The octanol-water distribution coefficients (logD7.4) of the radioligands were determined by the “shake flask” 








Stability over 3 h 
in human serumd
[18F]1e 3.4 2.34 ± 0.03 N/A N/A
[18F]11 0.43 0.78 ± 0.005 42% >99%
[18F]12 2.03 1.74 ± 0.070 38% >99%
[18F]13 1.94 1.49 ± 0.003 37% >99%
Table 2. In-vitro characteristics of potential Y1R radioligands [18F]11, [18F]12 and [18F]13. aClogD7.4 values 
were calculated using the software Marvin Sketch (ChemAxon). bExperimental logD7.4 values were determined 
by the “shake flask” method (n = 3, performed in triplicates). cThe binding to human plasma proteins was 
determined by means of gel filtration tubes (n = 3). dThe stability of the radiotracers in human serum was 
determined by radio-HPLC (n = 1). eValues for [18F]1 were taken from ref.18 for comparison. N/A not available.
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values (Table 2). As expected, the fluoroglycosylated compound [18F]11 was the most hydrophilic one in this 
series (logD7.4 = 0.78, calculated: 0.43) followed by the fluoroethoxy compound with the longer chain ([18F]13, 
logD7.4 = 1.49, calculated: 1.94) and the compound with the shortest side chain, [18F]12 (logD7.4 = 1.74, calcu-
lated: 2.03). Obviously, there was a strong influence of the bulkiness or hydrophilicity of the side chain on recep-
tor affinity: The more hydrophilic or the more sterically demanding the side chain, the lower is the affinity to 
the Y1R. The results of the previously published ligands 1 (logD7.4 = 2.34; Ki = 1.3 nM) and 3 (clogD7.4 = 0.37; 
Ki = 20,000 nM)18 support this hypothesis.
The binding of the radioligands to human plasma proteins was determined by gel filtration and revealed a high 
fraction of protein bound radioligand: less than half of the amount of radioactivity in plasma was unbound and 
thus freely available in the blood (42% of [18F]11, 38% of [18F]12 and 37% of [18F]13, Table 2).
The stability of the radiotracers was evaluated in vitro by radio-HPLC: None of the three radioligands showed 
any radioactive degradation products within 3 h of incubation in human serum at 37 °C (see Supplementary 
Fig. S3 and Table 2).
To determine cellular accumulation in vitro, assays with the 18F-labelled ligands were performed using the 
human breast cancer cells MCF-7-Y1. Cells were incubated either with the radioligand alone (total binding) or 
with the radioligand in the presence of 10 µM BIBP3226 as the blocking substance for determination of nonspe-
cific binding. The total radioactivity in each well was defined as 100%. The highest specific accumulation was 
observed for the fluoroethoxy radioligand [18F]12 (about 6% at 30 and 60 min, Fig. 3), whereas the fluoroethoxy 
radioligand [18F]13 revealed a specific cellular association of only 1%, and the fluoroglycosylated radioligand 
[18F]11 revealed almost no specific binding to MCF-7-Y1 cells (Fig. 3). This result can easily be explained by the 
lower affinities of [18F]11 and [18F]13 compared to the high-affinity ligand [18F]12.
To substantiate the specific binding of the radioligands to Y1R, autoradiography experiments were performed 
in vitro using slices of MCF-7-Y1 tumour xenografts. The tumour slices were incubated with each of the three 
radioligands in the presence or absence of BIBP3226 (1 µM and 10 µM). As expected, fluoroglycosylated ligand 
[18F]11 showed very low specific binding to the tumour slices, whereas both fluoroethoxy ligands [18F]12 and 
[18F]13 showed marked specific binding to the solid MCF-7-Y1-tumours (Fig. 4).
Biodistribution and small animal pet. The biodistribution of [18F]11, [18F]12 and [18F]13 was evaluated 
in vivo in healthy mice; the determined uptake values are depicted in Fig. 5. In general, the biodistribution of 
all three radioligands was very similar to that of [18F]118. However, a detailed HPLC analysis of blood samples 
taken early after radiotracer injection revealed that the 18F-labelled radioligands [18F]12 and [18F]13 underwent 
rapid degradation in the blood, forming very hydrophilic radiometabolites, whereas the 18F-glycosyl derivative 
[18F]11 interestingly revealed higher stability in the blood in vivo (Supplemantary Fig. S4). After 5 min p.i. only 
10% of intact [18F]12, less than 5% of intact [18F]13 and about 50% intact [18F]11 were determined in the blood 
samples. The radioligands and radiometabolites showed fast clearance from the blood, as there was no detecta-
ble radioactivity in the blood at 90 min p.i. Moderate amounts of radioactivity were detected in the kidneys and 
intestines, and exceptionally high radioactivity was observed in the gall bladder (up to 600%ID/g after 90 min for 
[18F]11). All other organs did not show any significant accumulation of the radioligands. The uptake in the liver 
as the main organ for metabolism of xenobiotics was below 5%ID/g at 30 min and below 1.5%ID/g at 90 min p.i. 
The three 18F-radioligands revealed a more differentiated result regarding the uptake in the kidney, which can be 
ascribed to the formation of hydrophilic radiometabolites in the blood (Supplemantary Fig. S4): Whereas [18F]11 
and [18F]13 revealed kidney uptake of <5%ID/g at 30 and 90 min p.i., the uptake of [18F]12 was about three times 
higher. As reported earlier for [18F]118, the majority of the injected radioactivity was found in the gall bladder 
(>100%ID/g) and in the intestines. For the glycosylated ligand [18F]11 the excretion seems to occur more slowly 
as the accumulation in these organs increased from 30 to 90 min p.i., while it stayed constant or decreased in case 
of the fluoroethoxy ligands [18F]12 and [18F]13. The high accumulation in the bile might hamper tumour imaging 
by PET, as it was previously described for [18F]118. The aim of reducing the uptake in the gall bladder by using 
more hydrophilic radioligand analogues, was obviously not reached, although the lipophilicity of the radiotracers 
was in fact reduced. Since only very little radioactivity was detected in the bones, it is most likely that there was no 
cleavage of fluoride from the molecules in terms of metabolism.
Figure 3. Total (solid line) and nonspecific (dashed line) uptake of the respective radioligands in MCF-7-Y1 
cells. 300,000 cells/well were incubated with 15 kBq of the respective radioligand. Nonspecific uptake was 
determined by coincubation with 10 µM BIBP3226. Each point represents the mean ± standard deviation from 
one experiment performed in n = 6.
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Finally, PET imaging was performed with the three radiotracers on MCF-7-Y1 xenografted nude mice. 
However, despite low background, visualision of the tumour with the fluoroglycosylated radiotracer [18F]11 
failed, most likely due to the low affinity of the radioligand to the Y1R (Fig. 6, left panel). Both fluoroethoxy radi-
oligands [18F]12 (Fig. 6, middle panel) and [18F]13 (Fig. 6, right panel) demonstrated displaceable and thus spe-
cific Y1R-mediated tumour acculuation in vivo, which was proven by co-injection of the radioactive compounds 
together with the non-radioactive competitor BIBP3226 (1 mg/kg; Fig. 6, middle and right panel). The specific 
uptake of [18F]13 in MCF-7 was less pronounced compared to [18F]12, nicely reflecting the in-vitro results on 
receptor binding data and cellular accumulation studies. Both radiotracers, [18F]12 and [18F]13, showed relatively 
high background values in the PET images, compromising their further application in vivo. This may be explained 
by the fast formation of radiometabolites (>90%) in the blood (see Supplementary Information Fig. S4).
Figure 4. In-vitro autoradiography with the three potential Y1R radioligands [18F]11, [18F]12 and [18F]13 on 
MCF-7-Y1 tumour slices (14 µm) together with slices stained with HE. Blocking experiments were performed 
in the presence of 1 µM and 10 µM BIBP3226. Figure adapted from corresponding PhD thesis26.
Figure 5. In-vivo biodistribution of the three Y1R radioligands [18F]11, [18F]12 and [18F]13 in normal mice a) 
30 min and b) 90 min p.i. of the radiotracer. Data are given as mean ± SEM from three animals. Figure adapted 
from corresponding PhD thesis26.
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Compared to the previously published ligand [18F]118, the radioligands [18F]12 and [18F]13 were more hydro-
philic and demonstrated enhanced and specific tumour uptake leading to improved tumour-to-background-ratios, 
such that Y1R-positive tumours could clearly be visualised by PET. Nevertheless, there is still room for improve-
ment for the design of an optimal radioligand for Y1R imaging by PET.
conclusion
Three BIBP3226-derivatives, two with 18F-fluoroethoxy-linkers and one with a 18F-fluoroglucosyl moiety, were 
radiosynthesised in sufficient radioactivity yields and molar activities. Dependent on the size of the carbamoyl 
residues attached to the guanidine group the three radioligands showed receptor affinities for Y1R from 2.8–
208 nM. The radioligand with the highest affinity ([18F]12) revealed the highest specific binding to Y1R-positive 
cells and to tumour slices in vitro. Despite their different hydrophilicity (logD7.4 values ranging from 0.43 to 2.03), 
the biodistribution of the three radioligands in healthy mice was very similar. In PET scans of tumour-bearing 
mice, [18F]12 showed the highest specific binding to the Y1R-positive tumour in vivo, corresponding to the high-
est in-vitro affinity of the 18F-labelled ligands under study. However, the PET imaging results suffered from high 
background levels, because of fast degradation of the radioligands in the blood and marked binding to plasma 
proteins. Therefore, the present study has to be regarded as another step towards the development of an optimal 
PET radioligand for Y1R imaging in vivo.
Methods
General. Radio-HPLC was performed on an Agilent 1100 system with a quarternary pump and a variable 
wavelength detector and a radio-HPLC detector D505TR (Canberra Packard). Computer analysis of the HPLC 
data was performed using FLO-One software (Canberra Packard). Electron-spray ionisation (ESI) mass spec-
trometry analysis was performed using a Bruker Esquire 2000 instrument.
chemistry. Synthetic procedures and analytical data for the guanidinylating reagent 5 and compounds 14–21 
are described in the Supplementary Information associated with this article. The (R)-ornithine derivative 419 and 
the glycosyl azide 820 were prepared according to previously described procedures.
(2R)-5-{[(1Z)-Amino({[({1-[(2R,5S)-6-(fluoromethyl)-3,4,5-trihydroxyoxan-2-yl]-1H-1,2,3-tri-
azol-4-yl}methyl)carbamoyl]imino})methyl]amino}-2-(2,2-diphenylacetamido)-N-[(4-hydroxy-
phenyl)-methyl]pentanamide (11). 7 (5.54 mg, 10 µmol, 1 eq.) was dissolved in a 3-mL micro reaction 
vessel in 380 µL tert-butanol. 6-Deoxy-6-fluoro-β-D-glucopyranosyl azide 8 (6.21 mg, 30 µmol, 3 eq.) was dis-
solved in 232 µL water and added to the reaction vessel. Solutions of copper(II) acetate (67.5 µL, 40 mM) and 
sodium ascorbate (81.0 µL, 100 mM) were mixed for 1 min and then added to the reaction vessel. The solution 
was stirred for 30 min in the capped vessel. The mixture was then diluted with 20 mL water and passed through 
a preconditioned (10 mL acetonitrile, 15 mL water) Sep-Pak® C18 Plus Long SPE cartridge. The trapped product 
was eluted from the SPE cartridge with 2 mL ethanol and the solvent was evaporated in vacuo. The crude product 
was purified by semipreparative HPLC (Kromasil 100 C8 5 µm, 125 × 8 mm, 4 mL/min, 20–40% CH3CN (0.1% 
TFA) in water (0.1% TFA) in a linear gradient over 30 min, tR = 16.23 min). The fractions containing the product 
were pooled, concentrated in vacuo, coevaporated with acetonitrile several times and dried in vacuo.
Yield: 4.0 mg as a brown oil (53%). HPLC: tR = 3.46 min (Chromolith RP-18e, 100 × 4.6 mm, 4 mL/
min, 10–90% CH3CN (0.1% TFA) in water (0.1% TFA) in a linear gradient over 10 min), 97%; tR = 2.26 min 
(Chromolith RP-18e, 100 × 4.6 mm, 4 mL/min, 25% CH3CN (0.1% TFA) for 1 min, then 25–60% CH3CN (0.1% 
TFA) in water (0.1% TFA) in a linear gradient over 5 min), >98%; LC-MS: m/z calcd: 762.33 [M + H]+, found: 
762.27 [M + H]+.
Figure 6. PET images of in MCF-7-Y1-tumour bearing nude mice injected with Y1R radioligands [18F]11, 
[18F]12 and [18F]13 at 45–60 min p.i. Tumours are indicated by crosshair. The blocking experiments were 
performed by co-injection of 1 mg/kg BIBP3226.




pentanamide (12). 7 (5.54 mg, 10 µmol, 1 eq.) and 9 (6.00 mg, 45 µmol, 4.5 eq.) were dissolved in 380 µL 
tert-butanol and 232 µL water and added to a 3 mL micro reaction vessel. Solutions of copper(II) acetate (67.5 µL, 
40 mM), sodium ascorbate (81.0 µL, 500 mM), THPTA (tris(3-hydroxypropyltriazolylmethyl)amine, 40 µL, 
20 mM, in EtOH) and DIPEA (2 µL) were mixed for 1 min and then added to the reaction vessel. Acetonitrile 
(250 µL) was added to the reaction vessel and the solution was stirred for 5 min in the capped vessel. The mixture 
was diluted with 20 mL water and passed through a preconditioned (10 mL acetonitrile, 15 mL water) Sep-Pak® 
C18 Plus Long SPE cartridge. The trapped product was eluted from the SPE cartridge with 2 mL ethanol and the 
solvent was evaporated in vacuo. The crude product was purified by semipreparative HPLC (Kromasil 100 C8 
5 µm, 125 × 8 mm, 4 mL/min, 30–40% CH3CN (0.1% TFA) in water (0.1% TFA) in a linear gradient over 30 min, 
tR = 10.7 min). The fractions containing the product were pooled, concentrated in vacuo, coevaporated with ace-
tonitrile several times and dried in vacuo.
Yield: 1.8 mg (26%); HPLC: tR = 3.85 min (Chromolith RP-18e, 100 × 4.6 mm, 4 mL/min, 10–90% CH3CN 
(0.1% TFA) in water (0.1% TFA) in a linear gradient over 10 min), 95%; tR = 2.96 min (Chromolith RP-18e, 
100 × 4.6 mm, 4 mL/min, 25% CH3CN (0.1% TFA) for 1 min, then 25–60% CH3CN (0.1% TFA) in water (0.1% 
TFA) in a linear gradient over 5 min), 93%; LC-MS: m/z calcd: 688.33 [M + H]+, found: 688.24 [M + H]+.
(2R)-5-{[(1Z)-Amino[({[1-(2-{2-[2-(2-fluoroethoxy)ethoxy]ethoxy}ethyl)-1H-1,2,3-triazol-4-
yl]methyl}carbamoyl)imino]methyl]amino}-2-(2,2-diphenylacetamido)-N-[(4-hydroxyphe-
nyl)-methyl]pentanamide (13). 7 (5.54 mg, 10 µmol, 1 eq.) and 10 (6.63 mg, 30 µmol, 3 eq.) were dissolved 
in 380 µL tert-butanol and 232 µL water and added to a 3 mL micro reaction vessel. Solutions of copper(II) acetate 
(67.5 µL, 40 mM), sodium ascorbate (81.0 µL, 500 mM), THPTA (40 µL, 20 mM, in EtOH) and DIPEA (2 µL) were 
mixed for 1 min and then added to the reaction vessel. Acetonitrile (250 µL) was added to the reaction vessel and 
the solution was stirred for 5 min in the capped vessel. The mixture was diluted with 20 mL water and passed 
through a preconditioned (10 mL acetonitrile, 15 mL water) Sep-Pak® C18 Plus Long SPE cartridge. The trapped 
product was eluted from the SPE cartridge with 2 mL ethanol and the solvent was evaporated in vacuo. The crude 
product was purified by semipreparative HPLC (Kromasil 100 C8 5 µm, 125 × 8 mm, 4 mL/min, 30–40% CH3CN 
(0.1% TFA) in water (0.1% TFA) in a linear gradient over 30 min, tR = 11.5 min). The fractions containing the 
product were pooled, concentrated in vacuo, coevaporated with acetonitrile several times and dried in vacuo.
Yield: 3.5 mg (45%); HPLC: tR = 3.93 min (Chromolith RP-18e, 100 × 4.6 mm, 4 mL/min, 10–90% CH3CN 
(0.1% TFA) in water (0.1% TFA) in a linear gradient over 10 min), 98%; tR = 3.06 min (Chromolith RP-18e, 
100 × 4.6 mm, 4 mL/min, 25% CH3CN (0.1% TFA) for 1 min, then 25–60% CH3CN (0.1% TFA) in water (0.1% 
TFA) in a linear gradient over 5 min), 97%; LC-MS: m/z calcd: 776.39 [M + H]+, found: 776.32 [M + H]+.
In-vitro determination of receptor affinity. Radioligand competition binding studies at the hY1R were per-
formed on SK-N-MC neuroblastoma cells as previously described using the radioligand [3H]UR-MK299 
(Kd (Y1R) = 0.044 nM)22. Competition binding experiments at the hY2R and hY5R were performed on 
CHO-hY2-Gqi5-mtAEQ cells and HEC-1b hY5R cells, respectively, as previously reported using [3H]
propionyl-pNPY (Kd (Y2R) = 1.4 nM, Kd (Y5R) = 4.8 nM) as radioligand23. Competition binding studies at 
the hY4R were performed on CHO-hY4R-Gqi5-mtAEQ cells as previously described using [3H]UR-KK200 
(Kd = 0.67 nM) as radioligand23. Data analysis (four-parameter sigmoidal fitting of specifically bound radioligand 
plotted against log(concentration) competitor) was performed using SigmaPlot (Systat Software, San Jose, CA, 
USA) (Y1R binding). IC50 values were converted to Ki values according to the Cheng-Prusoff equation24.
Radiochemistry
1-Azido-2-(2-[18F]fluoroethoxy)ethane ([18F]9). [18F]Fluoride was eluted from an anion-exchange car-
tridge (QMA, Waters) with a solution of 10 mg Kryptofix® 2.2.2., 18 µL 0.1 M K2CO3 and 18 µL 0.1 M KH2PO4 
in 1 mL acetonitrile/water (8:2 v/v). The solvent was evaporated in a stream of nitrogen at 85 °C and co-evapo-
rated to dryness with acetonitrile (3 × 0.5 mL). The labelling precursor 20 (9 mg, 32 µmol, kept under vacuum at 
40 °C overnight) in anhydrous acetonitrile (0.45 mL) was added, and the mixture was stirred at 85 °C for 5 min. 
The crude reaction mixture was diluted with 0.5 mL of acetonitrile/water (1:4 v/v, 0.1% TFA) and submitted to 
semipreparative HPLC (Kromasil 100 C8 5 µm, 125 × 8 mm, 4 mL/min, 10–50% acetonitrile (0.1% TFA) in water 
(0.1% TFA) in a linear gradient over 25 min, tR (20) = 14.8 min, tR ([18F]9) = 8.1 min). The product fraction was 
diluted with water to a total volume of 20 mL and passed through a Strata-X® (Phenomenex, 100 mg/3 mL) SPE 
column. The product [18F]9 was eluted with 2 mL THF and fractions of about 0.1 mL each were collected. Starting 
from 1370 MBq [18F]fluoride, this procedure yielded 527 MBq (38% radioactivity yield (RAY)) [18F]9 in a total 
synthesis time of 40 min.
1-Azido-2-{2-[2-(2-[18F]fluoroethoxy)ethoxy]ethoxy}ethane ([18F]10). [18F]Fluoride was eluted 
from an anion-exchange cartridge (QMA, Waters) with a solution of 10 mg Kryptofix® 2.2.2., 18 µL 0.1 M K2CO3 
and 18 µL 0.1 M KH2PO4 in 1 mL acetonitrile/water (8:2 v/v). The solvent was evaporated in a stream of nitrogen 
at 85 °C and co-evaporated to dryness with acetonitrile (3 × 0.5 mL). The labelling precursor 21 (9 mg, 24 µmol, 
kept under vacuum at 40 °C overnight) in anhydrous acetonitrile (450 µL) was added and the mixture was stirred 
for 5 min at 85 °C. The solvent was again evaporated in a stream of nitrogen, and the residue was re-dissolved in 
0.5 mL of acetonitrile/water (1:1 v/v, 0.1% TFA). The solution was submitted to semipreparative HPLC (Kromasil 
100 C8 5 µm, 125 × 8 mm, 4 mL/min, 10–50% acetonitrile (0.1% TFA) in water (0.1% TFA) in a linear gradient 
over 25 min, tR (21) = 14.2 min, tR ([18F]10) = 10.3 min). The product fraction was diluted with water to a total 
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volume of 20 mL and passed through a Strata-X® (Phenomenex, 100 mg/3 mL) SPE column. The product [18F]10 
was eluted with 1 mL ethanol. Starting from 918 MBq [18F]fluoride, this procedure yielded 369 MBq (40% RAY) 
[18F]10 in a total synthesis time of 35 min.
(2R)-5-{[(1Z)-Amino({[({1-[(2R,5S)-6-([18F]fluoromethyl)-3,4,5-trihydroxyoxan-2-yl]-1H-1,2,3-
triazol-4-yl}methyl)carbamoyl]imino})methyl]amino}-2-(2,2-diphenylacetamido)-N-[(4-
hydroxyphenyl)-methyl]pentanamide ([18F]11). 2,3,4-Tri-O-acetyl-6-deoxy-6-[18F]fluoroglucosyl 
azide was prepared, isolated by semi-preparative HPLC and deacetylated with NaOH (250 µL, 60 mM, 10% eth-
anol) at 60 °C for 5 min as described before20. The crude product 6-deoxy-6-[18F]fluoroglucosyl azide [18F]8 was 
subsequently used for the click chemistry reaction with alkyne 7 in a one-pot-procedure as described before21. 
In brief, to the solution containing [18F]8 (in 270 µL of 60 mM NaOH and 30 µL ethanol) was given a mixture 
of 30 µL 20 mM THPTA, 30 µL 4 mM Cu(OAc)2, 30 µL 0.1 M sodium ascorbate, 25 µL 7 (200 nmol in ethanol), 
270 µL 0.5 M phosphate buffer pH 8 and 50 µL ethanol. The mixture was stirred at 60 °C for 20 min. Subsequently, 
350 µL of acetonitrile/water (1:1 v/v, 0.1% TFA) were added, and the solution was submitted to semipreparative 
HPLC (Kromasil 100 C8 5 µm, 125 × 8 mm, 4 mL/min, 20–40% acetonitrile (0.1% TFA) in water (0.1% TFA) in 
a linear gradient over 30 min, tR (7) = 23.1 min, tR ([18F]11) = 16.7 min). The product fraction was diluted with 
water to a total volume of 20 mL and passed through a Sep-Pak® C18 Plus Light SPE cartridge (Waters). The car-
tridge was washed with 5 mL water and [18F]11 was eluted with 1 mL of ethanol/saline (1:1 v/v). The volume was 
reduced in vacuo. Starting from 430 MBq 2,3,4-tri-O-acetyl-6-deoxy-6-[18F]fluoroglucosyl azide, this procedure 
yielded 200 MBq (47% RAY) [18F]11 in a total synthesis time of 80 min with a molar radioactivity of 9 GBq/µmol.
(2R)-5-{[(1Z)-Amino({[({1-[2-(2-[18F]fluoroethoxy)ethyl]-1H-1,2,3-triazol-4-yl}methyl)carba-
moyl]-imino})methyl]amino}-2-(2,2-diphenylacetamido)-N-[(4-hydroxyphenyl)methyl]pen-
tanamide ([18F]12). 30 µL 20 mM THPTA, 30 µL 4 mM Cu(OAc)2, and 30 µL 0.1 M sodium ascorbate were 
mixed in an Eppendorf reaction vessel for 1 min, followed by addition of 25 µL 7 (200 nmol in ethanol) and 
270 µL 0.5 M phosphate buffer pH 8. The solution was mixed and added to a solution of [18F]9 in ca. 0.3 mL of 
THF at 60 °C. The mixture was stirred at 60 °C for 20 min prior to dilution with 0.4 mL of water (containing 0.1% 
TFA). The mixture was submitted to semipreparative HPLC (Kromasil 100 C8 5 µm, 125 × 8 mm, 4 mL/min, 
20–40% acetonitrile (0.1% TFA) in water (0.1% TFA) in a linear gradient over 30 min, tR ([18F]9) = 6.3 min, tR 
(7) = 23.1 min, tR ([18F]12) = 22.0 min), the product fraction was diluted with water to a total volume of 20 mL 
and passed through a Sep-Pak® C18 Plus Light SPE cartridge (Waters). The cartridge was washed with 5 mL water 
and [18F]12 was eluted with 1 mL ethanol/saline (1:1 v/v). The volume was reduced in vacuo. Starting from 104 
MBq [18F]9, this procedure yielded 17 MBq (16% RAY) [18F]12 in a total synthesis time of 60 min.
(2R)-5-{[(1Z)-Amino[({[1-(2-{2-[2-(2-[18F]fluoroethoxy)ethoxy]ethoxy}ethyl)-1H-1,2,3-tri-
azol-4-yl]methyl}carbamoyl)imino]methyl]amino}-2-(2,2-diphenylacetamido)-N-[(4-hydroxy-
phenyl)-methyl]pentanamide ([18F]13). A solution of [18F]10 in ethanol was evaporated in a stream of 
nitrogen at 60 °C. The solution containing the components for the CuAAC reaction was prepared as follows: 30 µL 
20 mM THPTA, 30 µL 4 mM Cu(OAc)2, and 30 µL 0.1 M sodium ascorbate were mixed in an Eppendorf tube for 
1 min, followed by addition of 25 µL 7 (200 nmol in ethanol) and 270 µL 0.5 M phosphate buffer pH 8. The CuAAC 
solution was mixed and added to the dried residue. The mixture was stirred at 60 °C for 15 min. 0.2 mL acetoni-
trile/water (1:1 v/v, 0.1% TFA) were added and the solution was submitted to semipreparative HPLC (Kromasil 
100 C8 5 µm, 125 × 8 mm, 4 mL/min, 20–40% acetonitrile (0.1% TFA) in water (0.1% TFA) in a linear gradient 
over 30 min, tR ([18F]10) = 7.4 min, tR (7) = 23.1 min, tR ([18F]13) = 22.8 min). The product fraction was diluted 
with water to a total volume of ca. 20 mL and passed through a Sep-Pak® C18 Plus Light SPE cartridge. The car-
tridge was washed with 5 mL water and [18F]13 was eluted with 1 mL ethanol/saline (1:1 v/v). The volume was 
reduced in vacuo. Starting from 369 MBq [18F]10, this procedure yielded 91 MBq (25% RAY) [18F]13 in a total 
synthesis time of 60 min with a molar radioactivity of 5 GBq/µmol.
In-vitro characterisation of radiotracers. Lipophilicity determination. The lipophilicity of the radiolig-
ands was determined by the distribution coefficient logD7.4. The respective radioligand (10 µL, about 25 kBq) was 
added to a mixture of PBS (500 µL) and 1-octanol (500 µL) and the emulsion was vortexed for 1 min. After cen-
trifugation 3 × 100 µL were taken of each layer and analysed by a γ-counter. The partition coefficient was calcu-
lated as ( )logD log cpmcpm7 4 octanolPBS=. . Data were expressed as mean values ± SD from three experiments.
Determination of plasma protein binding. The binding of 18F-labelled compounds to plasma proteins was deter-
mined using gel filtration columns(illustra™ MicroSpin™ G-50 Columns, GE Healthcare Life Sciences, Freiburg). 
An aliquot of the radiotracer (approx. 100 kBq) was added to 200 µL of saline, and 100 µL of human plasma, 
respectively. Both samples were incubated at 37 °C for 10 min. MicroSpin™ columns were prepared according to 
the user instruction. Then 25 µL of the incubated radiotracer were given onto the columns and the devices were 
centrifuged (2000 × g, 2 min). Eluate and solid phase were analysed in the γ-counter (Wallac Wizard). The per-







. The sample in saline was used as 
control.
Determination of radiotracer stability in human serum. The stability of 18F-labelled compounds was determined 
in human serum. An aliquot of the radiotracer (5–10 MBq) was added to 200 µL human serum and incubated 
at 37 °C. Aliquots of 15 µL were taken after 5, 10, 15, 30, 45, 60, 120 and 180 min and quenched in 100 µL of 
10% aqueous TFA. The samples were centrifuged (20000 × g, 2 min), and the supernatants were analysed by 
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radio-HPLC (Chromolith RP-18e, 100 × 4.6 mm, 4 mL/min, 0–1 min 25% CH3CN (0.1% TFA) in water (0.1% 
TFA), 1–6 min 25–60%, 6–7 min 60–100%, 7–8 min 100%).
Cell line. MCF-7-Y1 is a subclone that originated in Prof. Dr. Armin Buschauer’s group (Regensburg University, 
Regensburg) from human breast cancer cell line MCF-7 in the 157th passage and shows 2–3 fold higher Y1R 
expression25. MCF-7-Y1 cells were cultivated in MEM Earle´s liquid medium with 2.2 g/L NaHCO3 (Merck 
Biochrom, Darmstadt) containing 10% FBS and 1% L-glutamine. All cells were cultured under sterile conditions 
in a humidified atmosphere containing 5% CO2 at 37 °C. Cells were routinely passaged twice a week.
Cellular accumulation assay. The cellular accumulation of Y1R radioligands by MCF-7-Y1 cells was measured: 
On the day prior to the experiment, 300,000 cells per well were seeded into 24-well plates (Greiner Bio-One). 
Attached cells were washed twice with cold PBS and 450 µL of assay medium (cell culture medium containing 
0.1% BSA) were added to the cells for total binding. For non-specific binding, 400 µL of assay medium and 50 µL 
of medium containing 10 µM BIBP3226 were added. Finally, 50 µL of medium containing approx. 15 kBq of the 
respective radiotracer were added to each well, and cells were incubated at 37 °C for 10, 30, 60 or 90 min. After 
incubation, cells were washed with 500 µL of ice-cold PBS and lysed with 600 µL of warm 1 M NaOH. The lysed 
cells were transferred to counting tubes and analysed in the γ-counter (Wallac Wizard, Perkin Elmer, Waltham, 
MA, USA). Separate tubes containing 50 µL of medium with the radiotracer (approx. 15 kBq) were analysed as 
reference samples. Experiments were performed in sextuplicate (n = 6).
In-vitro autoradiography. MCF-7-Y1 tumour bearing mice were sacrificed by cervical dislocation under deep 
isoflurane anesthesia and tumours were excised and subsequently frozen in a hexane/dry ice bath (−70 °C). 
MCF-7-Y1 tumour slices (14 µm) were prepared on a cryostat microtome HM 500 O (Microm, Walldorf) and 
thaw-mounted on Histobond® adhesive glass slides (Marienfeld, Lauda-Königshofen).
For autoradiography studies slides were thawed and pre-incubated for 15 min in incubation buffer (50 mM 
TRIS HCl, pH 7.4, containing 120 mM NaCl, 5 mM MgCl2,) at room temperature. Thereafter, 800 µL of incuba-
tion buffer, containing 0.1 MBq of the respective radiotracer were pipetted on the slide and incubated at room 
temperature for 60 min. For displacement studies BIBP3226 (1 µM or 10 µM) was added to the incubation buffer 
before pipetting on the slides. Afterwards slides were washed by placing in ice cold incubation buffer (3 × 2 min) 
followed by short dipping in ice cold distilled water. Slides were carefully dried in a stream of warm air and finally 
placed on an autoradiography film (Fuji Imaging Plate BAS-IP SR 2025 E, Fujifilm, Düsseldorf) overnight prior to 
readout (25 µm resolution) on the autoradiograph (HD-CR-35 Bio, Raytest, Straubenhardt) and analysis with the 
software AIDA (Raytest). Additional sections were stained with hematoxylin and eosin (H&E) for comparison 
with the autoradiography images.
In-vivo characterisation of radiotracers. All mouse experiments were approved by the local animal pro-
tection authorities (Government of Central Franconia, Germany, No. 55.2 2532-2-279) and performed at the FAU 
in accordance with the relevant E.U. guidelines and regulations.
Biodistribution. Biodistribution studies were conducted using female NMRI outbred mice (HsdWin:NMRI) 
purchased from Envigo (Horst, The Netherlands). Mice were kept in groups of four to five animals in individually 
ventilated cages in a twelve hours dark/light cycle with unlimited access to water and standard chow. At the age 
of eight to nine weeks six animals per radiotracer were injected with 2–4 MBq of the respective radiotracer under 
isoflurane anesthesia. Mice were sacrificed by cervical dislocation 30 or 90 min p.i. of the radiotracer. Blood as 
well as the organs/tissues lung, liver, kidneys, heart, spleen, brain, muscle, intestines, gall bladder and bones were 
harvested and analysed in the γ-counter. Samples were weighed and radioactivity in different tissues was calcu-
lated as percentage of the total injected dose per gram tissue (%ID/g).
Small animal PET. For the NPY Y1R xenograft model, female NMRI nude mice (HsdCpb:NMRI-Foxn1nu) were 
purchased from Envigo (Horst, The Netherlands) at the age of three weeks. Mice were kept in groups of four to 
five animals in individually ventilated cages in a twelve hours dark/light cycle with unlimited access to water 
and standard chow. At the age of nine to ten weeks one 17β-estradiol pellet per animal (0.72 mg per pellet, 3 mm 
diameter) with a 60-day release time (Innovative Research of America, Sarasota, FL, USA) was subcutaneously 
implanted on the back under isoflurane anesthesia. After three days, approximately 106 MCF-7-Y1 tumour cells 
(in 50 µL PBS) were mixed with Matrigel (50 µL, BD Biosciences, Heidelberg) and then injected subcutaneously 
at the back. Tumour diameters and weight of the animals were recorded five times a week. Imaging studies were 
performed four weeks after inoculation of the cells.
Small animal PET scans were performed on an Inveon™ microPET scanner (Siemens Healthcare, Erlangen) 
under isoflurane anesthesia (3%). Tumour bearing mice (26–35 g, n = 2–3 for each radioligand) were intrave-
nously injected into the tail vein with the respective radiotracer (1.5–4.2 MBq in about 100 µL of saline) under 
isoflurane anesthesia (3–4%). Static images were acquired for 15 min starting 45 min p.i. of the radiotracer. 
For displacement studies, the same mice were co-injected with the radiotracer ([18F]12 and [18F]13 only) and 
BIBP3226 (1 mg/kg). Images were corrected for decay and attenuation and MAP (iterative maximum a poste-
riori) images were reconstructed using the built-in software of the PET scanner. Evaluation of the MAP images 
was conducted using the software PMOD (version 3.6, PMOD Technologies LLC, Zürich). Regions of interests 
(ROIs) were drawn and radioactivity concentration within these regions was obtained from the mean values and 
calculated as percentage of the total injected dose per gram tissue (% ID/g).
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Determination of radioactive metabolites of Y1R radioligands in mouse blood. Nude mice were anesthetised with 
isoflurane and injected with the respective radiotracer (3–25 MBq) into the tail vein. After 5 min, animals were 
sacrificed by cervical dislocation and approx. 100 µL blood were collected from the abdomen and transferred into 
Li-heparinised Microvettes® (100 LH, Sarstedt). The same volume of aqueous urea (0.8 g/mL) was added and the 
Microvette® was centrifuged (2000 × g, 5 min). The supernatant was transferred to a 1.5 mL reaction vial, mixed 
with the same volume of 10% aqueous TFA and centrifuged (20000 × g, 5 min). This step was repeated once. 
A sample of the resulting supernatant (100 µL) was analysed by radio-HPLC using two methods (Chromolith 
RP-18e, 100 × 4.6 mm, 4 mL/min, 0–1 min 25% CH3CN (0.1%TFA) in water (0.1%TFA), 1–6 min 25–60%, 
6–7 min 60–100%, 7–8 min 100%; Kromasil 100 C8 5 µm, 250 × 4.6 mm, 1.5 mL/min, 1–25 min 20–53.3% CH3CN 
(0.1% TFA) in water (0.1% TFA), 25–27 min 53.3–80%, 27–28 min 80–100%, 28–32 min 100%).
Data Availability
All data generated or analysed during this study are included in this published article (and its Supplementary 
Information files). Parts of this study have been reported in the PhD thesis ‘Selective neuropeptide and opioid 
receptor radioligands for imaging studies in vivo by positron emission tomography (PET)’ by Julian J. Ott26.
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